Artiva Biotherapeutics Inc ARTV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $9.35
- Day Range
- $9.28–10.00
- 52-Week Range
- $2.06–14.48
- Bid/Ask
- $9.58 / $9.75
- Shares Outstanding
- 48.59M
- Market Cap
- $471.55M
- Volume/Avg
- 331,708 / 612,855
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 106
- Website
- https://www.artivabio.com
Valuation
|
Metric
|
ARTV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.63 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ARTV
|
|---|---|
Quick Ratio | 7.98 |
Current Ratio | 8.16 |
Interest Coverage | — |
Quick Ratio
ARTV
Profitability
|
Metric
|
ARTV
|
|---|---|
Return on Assets (Normalized) | −54.06% |
Return on Equity (Normalized) | −62.58% |
Return on Invested Capital (Normalized) | −60.79% |
Return on Assets
ARTV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|K#n!l$x | LOCK|h&^@T | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#wSkwF | LOCK|wBJp | $69B | |||
| argenx SE ADR
ARGX
| LOCK|lq?&?^ | LOCK|d! | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@rbZ!^j | LOCK|r>D#! | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#%gzTdx | LOCK|%& | $36B | |||
| Moderna Inc
MRNA
| LOCK|w&&X$H% | LOCK|wmc | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|hBq#vYK | LOCK|<^J&% | $25B | |||
| Incyte Corp
INCY
| LOCK|p^#XyF | LOCK|qy< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|qkw<c& | LOCK|$>c | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|j>c!j# | LOCK|mY | $16B |
United States